Boris D. Heifets
As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.
Psychedelic compounds show promise for treating neuropsychiatric disorders, but limited patient access is a challenge. Non-hallucinogenic psychedelics, or neuroplastogens, are emerging as a potential solution to address concerns.
Wellness and Psychedelics: Academic studies show psychedelics, in clinical settings with therapy, rapidly improve psychiatric conditions. Survey of 3,000 adults found significant improvements in mental health with psychedelic use.
Saundra Jain
Psychedelics, historically linked to "free love", show potential for positive impact on sexual feelings. Recent research suggests psilocybin may enhance sexual functioning and satisfaction in healthy and depressed individuals.
Tommaso Barba
Neurological disorders like chronic pain and Alzheimer’s are being studied for psychedelic therapy benefits, expanding research beyond traditional mental health applications. Current studies explore potential applications for neurorehabilitation.
Julia Bornemann, James Close, Joel Castellanos, Robin Carhart-Harris
Ketamine and psilocybin show promise for health conditions but come with risks, including addiction. This talk challenges the view of drugs as neutral tools and explores their complex nature and
Elias Dakwar
Roland Griffiths, Ph.D., from Johns Hopkins University, leads research on psilocybin's effects, including therapeutic studies for psychological distress, depression, addiction, and brain imaging for neural mechanisms.
Roland Griffiths
Robin Carhart-Harris, Head of Centre for Psychedelic Research at Imperial College London, conducted pioneering clinical studies with psilocybin and other psychedelic drugs for over 40 years. He collaborates with Professor
Dr. Sloshower presents results from a psilocybin-assisted therapy study for major depression, showing larger antidepressant effects than placebo, with lasting mood improvements. Dr. Kilpatrick discusses longitudinal case studies.
Jordan Sloshower, Stephanie Kilpatrick
Psychedelics and 5-HT2A agonists show varying anti-inflammatory effects unrelated to their behavioral impact. Research identifies cellular mechanisms and aims to develop new compounds with targeted therapeutic properties.
© 1986 – 2025 Multidisciplinary Association for Psychedelic Studies. All Rights Reserved.
3141 Stevens Creek Blvd #40563, San Jose, CA 95117.
Mailing: MAPS P.O. Box 103004 Pasadena, CA 91189-3004.